Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
About this study
The purpose of this study is to evaluate the Safety and Efficacy of DREAM01, a gene therapy for Sickle Cell Disease (SCD). The therapy consists of transplanting autologous CD34+ cells transduced ex vivo with a bifunctional lentiviral vector expressing βAS3m-globin and an anti-βS miRNA. It aims to reduce or eliminate vaso-occlusive events and long-term organ damage in severe SCD patients lacking a Human Leukocyte Antigen (HLA) identical sibling donor.
- Condition
- Sickle Cell Disease
- Tested
- DREAM01 drug product, anti-inflammatory therapy
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Who can join
- Age
- 12 to 35 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 17
- Minimum age: 12 years
- Maximum age: 35 years
- Study condition: Sickle Cell Disease
- Age 12 - 35 years
- Acceptation of myelogram (bone marrow aspiration)
- Diagnosis of HbSS by Hb electrophoresis and genetic analysis to analyse the alpha locus
- Clinical history or ongoing evidence of severe sickle cell anemia with one OR more of the following clinical complications demonstrating disease severity:
- At least 3 vaso-occlusive crises requiring hospitalization, under hydroxyurea or transfusion, within 2 years prior to enrolment
- One severe acute chest syndrome (ACS) hospitalized in the intensive care unit
- At least 2 episodes of ACS, including one under HU.
- Acute priapism (at least 2 episodes \>3h in the preceding year or in the year prior to the start of a regular transfusion program), OR stuttering priapism ≥ 1 by week under sickle cell treatment (HU, transfusion or phlebotomy).
- Tricuspid regurgitation velocity \>2.8m/s on cardiac echocardiograph without pulmonary hypertension confirmed by right heart catheterization (mPAP\>\<25mmHg)
- Failed hydroxyurea (HU) therapy, OR Inadequate clinical response to HU, defined as any one of the following outcomes, while on HU for at least 3 months: 2 or more acute sickle pain crisis requiring hospitalization, requirement of transfusion to maintain Hb \>6.0g/dL, an episode of ACS despite adequate supportive care measures
- Karnovsky/Lansky performance score ≥ 60%
- Sexually active patients must be willing to use an acceptable method of double-barrier contraception for at least 12 months post-infusion (beyond 12 months at the discretion of the investigator)
- Procedure for obtaining consent (adults, dependent minors, to give their consent)
- Affiliation to social security
Exclusion 26
- Existence of a matched sibling donor
- Based on myelogram, the presence of chromosomal (detected by karyotyping) or molecular abnormalities (detected by NGS) and retained dangerous by the Hemato-Oncology referent and validated during a specific multidisciplinary concerted meeting
- Hematologic evaluation: Leukopenia (WBC \<3,000/µL) or neutropenia (ANC \<1,000/µL) or thrombocytopenia (platelet count \<100,000/µL) within 90 days prior to mobilization or harvest (not due to an erythrapheresis procedure or possible acute viral infection)
- PT/INR or PTT \>1.5 times the upper limit of normal (ULN) or clinically significant bleeding disorder
- Two alpha deletions (risk of alpha-thalassemia after gene therapy)
- Hypersensitivity to the active substances of the administered drugs (plerixafor, busulfan, anti-inflammatory therapy) or to any of their excipients
- Patients who have already been treated with gene therapy
- Evaluations within 6 months prior to screening visit:
- ALT or AST \>3 times ULN
- Severe liver iron overload evaluated by MRI (\>15mg Fe/g dry weight or \>270umol Fe/g dry weight) or liver cirrhosis suspicion on echography or elastometry or CT scan or MRI AND confirmed by histology
- Measured GFR \<60ml/min/1.73 m²
- Cardiac evaluation: LVEF \<40% by cardiac echocardiogram or by MUGA scan or clinically significant ECG abnormalities
- Stroke with significant CNS sequelae i.e., Rankin \>2
- Specific sickle cell disease cerebral vasculopathy confirmed by MRA (magnetic resonance angiography) OR transcranial doppler ultrasound with or without Moya-moya WITH an indication of chronic transfusion program (target HbS\<30%)
- Lung interstitial infiltrate AND Forced Vital Capacity less than 70% AND DLCO less than 60% at steady state
- Confirmed pulmonary hypertension defined by a right heart catheterization (PAPm \>25 mmHg).
- Right heart catheterization is required if tricuspid regurgitation velocity \>2.8m/s on cardiac echocardiograph OR \>2.5m/s with an abnormal Brain Natriuretic Peptide dosage or an important decrease in transcutaneous Hb O2 saturation during the 6 minutes' walk test.
- Seropositivity for HIV (Human Immunodeficiency Virus), HCV (Hepatitis C Virus), HTLV-1 (Human T-Lymphotropic Virus), or active Hepatitis B Virus, or active infection by CMV or parvovirus B19, based on positive blood PCR.
- Pregnancy or breastfeeding in a postpartum female
- Any current cancer or prior history of a malignant disease, with the exception of curatively treated non-melanoma skin cancer
- Immediate family member with an established or suspected Familial Cancer Syndrome
- Diagnosis of significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study
- Patients who failed previous HSCT
- Any clinically significant active infection
- Participation in another clinical study with an investigational drug within 30 days of screening
- Any condition, based on perspective of the medical monitor and treating investigator, which may lead to increased safety risk or inability to comply with the protocol
Where
1 site, 1 recruiting
Department of Biotherapy, Necker-Enfants Malades Hospital
Paris, Île-de-France Region, France
Contact
-
Marina CAVAZZANA, MD, PhD
01 44 49 50 68 m.cavazzana@aphp.fr
-
Nelly BRIAND, PhD
01 44 38 18 62 nelly.briand@aphp.fr
Potential match only. Final eligibility is determined by the study team.